Breast Cancer Outcome in Relation to Bone Mineral Density and Bisphosphonate Use: a Sub-study of the DATA Trial

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2020 Mar 4

PMID 32124136

Citations 2

Authors

Irene E G van Hellemond

Carolien H Smorenburg

Petronella G M Peer

Astrid C P Swinkels

Caroline M Seynaeve

Maurice J C van der Sangen

Judith R Kroep

Hiltje de Graaf

Aafke H Honkoop

Frans L G Erdkamp

Franchette W P J van den Berkmortel

Wilfred K de Roos

Sabine C Linn

Alexander L T Imholz

Maaike de Boer

Vivianne C G Tjan-Heijnen

Affiliations

Soon will be listed here.

Abstract

Purpose: The phase III DATA study compared 6 and 3 years of adjuvant anastrozole following 2-3 years of tamoxifen in postmenopausal breast cancer patients. This pre-planned side-study assessed the relationship between a reduced bone mineral density (BMD) and distant recurrence-free survival (DRFS), and evaluated the effect of bisphosphonates on DRFS.

Methods: We selected all patients with a BMD measurement within 3 years after randomisation (landmark) without any DRFS events. Kaplan-Meier methods and Cox proportional hazards models were used for analyses.

Results: Of 1860 eligible patients, 1142 had a DEXA scan before the landmark. The BMD was normal in 436 (38.2%) and showed osteopenia in 565 (49.5%) and osteoporosis in 141 (12.3%) patients. After a median follow-up of 5.0 years from the landmark, neither osteopenia nor osteoporosis (compared with normal BMD) were associated with DRFS in both the 6-year [osteopenia HR 0.82 (95% CI 0.45-1.49), osteoporosis HR 1.10 (95% CI 0.26-4.67)] and the 3-year arm [osteopenia HR 0.75 (95% CI 0.40-1.42), osteoporosis HR 1.86 (95% CI 0.43-8.01)]. Moreover, bisphosphonate use did not impact DRFS.

Conclusion: No association was observed between a reduced BMD and DRFS. Neither did we observe an impact of bisphosphonates on DRFS.

Citing Articles

Bisphosphonates and Prevention of the Perimenopausal Breast Cancer Recurrence: A Systematic Review and Meta-Analysis.

Sanaat Z, Nouri O, Khanzadeh M, Mostafaei H, Vahed N, Kabiri N J Breast Cancer. 2022; 25(6):454-472.

PMID: 36265887 PMC: 9807326. DOI: 10.4048/jbc.2022.25.e39.

Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?.

Clemenceau A, Michou L, Diorio C, Durocher F Int J Mol Sci. 2020; 21(22).

PMID: 33203195 PMC: 7696282. DOI: 10.3390/ijms21228613.

References

Neville-Webbe H, Evans C, Coleman R, Holen I . Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006; 27(2):92-103. DOI: 10.1159/000092489. View

Tjan-Heijnen V, van Hellemond I, Peer P, Swinkels A, Smorenburg C, van der Sangen M . Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017; 18(11):1502-1511. DOI: 10.1016/S1470-2045(17)30600-9. View

Kremer R, Gagnon B, Meguerditchian A, Nadeau L, Mayo N . Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study. J Natl Cancer Inst. 2014; 106(11). DOI: 10.1093/jnci/dju264. View

Paterson A, Anderson S, Lembersky B, Fehrenbacher L, Falkson C, King K . Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012; 13(7):734-42. PMC: 4970583. DOI: 10.1016/S1470-2045(12)70226-7. View

Solomayer E, Gebauer G, Hirnle P, Janni W, Luck H, Becker S . Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol. 2012; 23(9):2271-2277. DOI: 10.1093/annonc/mdr612. View

Brufsky A, Harker W, Beck J, Bosserman L, Vogel C, Seidler C . Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2011; 118(5):1192-201. DOI: 10.1002/cncr.26313. View

Agarwal P, Moshier E, Ru M, Ohri N, Ennis R, Rosenzweig K . Immortal Time Bias in Observational Studies of Time-to-Event Outcomes: Assessing Effects of Postmastectomy Radiation Therapy Using the National Cancer Database. Cancer Control. 2018; 25(1):1073274818789355. PMC: 6053873. DOI: 10.1177/1073274818789355. View

Lipton A, Chapman J, Demers L, Shepherd L, Han L, Wilson C . Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol. 2011; 29(27):3605-10. DOI: 10.1200/JCO.2010.31.5069. View

Lipton A, Chapman J, Leitzel K, Garg A, Pritchard K, Ingle J . Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27. Cancer. 2017; 123(13):2444-2451. DOI: 10.1002/cncr.30682. View

10.

Chen H, Chen F, Yang K, Yuan S . Association of Bone Metastasis With Early-Stage Breast Cancer in Women With and Without Precancer Osteoporosis According to Osteoporosis Therapy Status. JAMA Netw Open. 2019; 2(3):e190429. PMC: 6484629. DOI: 10.1001/jamanetworkopen.2019.0429. View

11.

Kroep J, Charehbili A, Coleman R, Aft R, Hasegawa Y, Winter M . Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. Eur J Cancer. 2016; 54:57-63. PMC: 4928630. DOI: 10.1016/j.ejca.2015.10.011. View

12.

Chlebowski R, Chen Z, Cauley J, Anderson G, Rodabough R, McTiernan A . Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010; 28(22):3582-90. PMC: 2917313. DOI: 10.1200/JCO.2010.28.2095. View

13.

Bouvard B, Chatelais J, Soulie P, Hoppe E, Saulnier P, Capitain O . Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors. Eur J Cancer. 2018; 101:87-94. DOI: 10.1016/j.ejca.2018.06.028. View

14.

Hortobagyi G, Theriault R, Porter L, Blayney D, Lipton A, Sinoff C . Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996; 335(24):1785-91. DOI: 10.1056/NEJM199612123352401. View

15.

Gnant M, Pfeiler G, Steger G, Egle D, Greil R, Fitzal F . Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(3):339-351. DOI: 10.1016/S1470-2045(18)30862-3. View

16.

Ottewell P, Wang N, Brown H, Reeves K, Fowles C, Croucher P . Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res. 2014; 20(11):2922-32. PMC: 4040234. DOI: 10.1158/1078-0432.CCR-13-1246. View

17.

Rouach V, Goldshtein I, Wolf I, Catane R, Chodick G, Iton A . Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer. J Bone Oncol. 2018; 12:91-95. PMC: 6107893. DOI: 10.1016/j.jbo.2018.07.011. View

18.

van Hellemond I, Smorenburg C, Peer P, Swinkels A, Seynaeve C, van der Sangen M . Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. Int J Cancer. 2019; 145(5):1325-1333. PMC: 6767695. DOI: 10.1002/ijc.32205. View

19.

Zmuda J, Cauley J, Ljung B, Bauer D, Cummings S, Kuller L . Bone mass and breast cancer risk in older women: differences by stage at diagnosis. J Natl Cancer Inst. 2001; 93(12):930-6. DOI: 10.1093/jnci/93.12.930. View

20.

Powles T, Paterson S, Kanis J, McCloskey E, Ashley S, Tidy A . Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002; 20(15):3219-24. DOI: 10.1200/JCO.2002.11.080. View